Relypsa Priced, Nasdaq: RLYP
Late-stage biotech developing a treatment for hyperkalemia.
Industry: Health Care
First Day Return: +9.7%
RLYP
Late-stage biotech developing a treatment for hyperkalemia.
| IPO Data | |
|---|---|
| IPO Date | 11/14/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $75 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Redwood City, CA, United States |
| Founded | 2007 |
| Employees at IPO | 69 |
| Website www.relypsa.com | |
IPO News for Relypsa
- Biotech IPOs are back to normal 11/25/13
- US IPO Recap: IPO count rises above 200 11/18/13
- Relypsa prices IPO at $11, below expectations 11/15/13
Relypsa (RLYP) Performance
